Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Connect Biopharma Holdings Inc CNTB

Healthcare Biotechnology
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company’s lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CNTB)

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

GlobeNewswire November 24, 2025

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 12, 2025

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

GlobeNewswire September 29, 2025

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

GlobeNewswire September 4, 2025

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

GlobeNewswire September 3, 2025

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

GlobeNewswire August 27, 2025

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

GlobeNewswire August 14, 2025

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 13, 2025

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

GlobeNewswire July 22, 2025
View More News ››

Opinion & Analysis (NDAQ:CNTB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CNTB)

High analyst target 10.00

At 2,93, it's a bargain. IMO
Form001 - November 21, 2025

Market cap only 156M

Good volume....
Form001 - November 19, 2025

Would like to the same upwave like RGC

.09 to 83.60.
Form001 - November 19, 2025

Q3 results, positive…

https://finance.yahoo.com/news/connect-biopharma-reports-third-quarter-140000691.html
Form001 - November 19, 2025

Would like to see a reverse split

3 to 1. IMO
Form001 - November 19, 2025

Consensus rating : STRONG BUY

10.00......
Form001 - November 19, 2025
View more Bullboard ››

Nuclear Vision Ltd.

Nuclear Vision Ltd.

Nuclear Vision Limited operates as a uranium exploration company. Its material property is the Regnault Project that consists ...
View More »